



Prof. John O. Prior, PhD MD
Nuclear Medicine and Molecular Imaging
Lausanne University Hospital, Switzerland

Practical radioprotection issues in nuclear medicine at the era of digital PET/ SPECT cameras


Unil
UNIL | Université de Lausanne



Part 1

Digital SiPM-based PET/CT Technology

PET: 3 major improvements last 3 decades



Digital SiPM PET vs. Conventional PMT PET

ORIGINAL RESEARCH

Open Access

Phantom-based image quality assessment of clinical ^{18}F -FDG protocols in digital PET/CT and comparison to conventional PMT-based PET/CT



Silvana Gnesin¹, Christine Kieffer¹, Konstantinos Zeimpekis², Jean-Pierre Papazyan³, Renaud Guignard⁴, John O. Prior^{5*}, Francis R. Verdun¹ and Thiago V. M. Lima^{1,6}

- 3 digital SiPM+2 convent. PMT PET
- FDG clinical oncologic protocols
- Evaluate trade-off between patient administered activity (*patient dose/signal-to-noise S/N ratio*) vs. acquisition time (*patient comfort*)

- List-mode reconstructions NEMA NU2 phantom (5 kBq/mL in background, 25 kBq/mL in spheres) for 10, 30, 90, 120, 180 & 300 s with 1–10 iterations
- Background coefficient of variation (COV)
- Spheres recovery coefficients (RCs)
- Using Time-activity-product (TAP) = scan time/bed position \times mass-activity administered (min \cdot MBq/kg)

Digital SiPM PET vs. Conventional PMT PET

3 different manufacturer:
 2 PMT-based PET
 3 digital PET

Installed in 2017-2018
(2 new manufacturer of SiPM PET/CT scanners in 2019, not included in this study)

Clinical FDG oncologic PET reconstructions protocols
 Different matrix and pixel sizes


Table 1 Systems, acquisition and reconstruction parameters applied in clinical whole-body oncologic ¹⁸F-FDG PET procedures

	Philips Vereos ^d	Siemens Vision ^d	Siemens mCT	GE Discovery-MI ^{da}	GE Discovery 690
System parameters	dPET	dPET	cPET	dPET	cPET
Axial ring extent (mm)	164	261	221	250	153
Energy window (keV)	450–613	435–585	435–650	425–650	425–650
TOF's resolution (ps)	316	215	540	370	544.3
NEMA System sensitivity (kcps/MBq)	5.6	16.4	9.6	22	7.5
Acquisition parameters					
Acq. Time (min)	1.5	2	2.5	2.5	1.5
Admin. Activity (MBq/kg)	2	2	5	1.5	3.5
Acq. Time (min) × A admin. (TAP in min × MBq/kg)	3	4	12.5	3.75	5.25
Reconstruction parameters					
Reconstruction methods	OSEM 3D TOF + PSF	OSEM 3D TOF + PSF	OSEM 3D TOF + PSF	OSEM 3D TOF + PSF	OSEM 3D TOF + PSF
Iterations and subsets (it,ss)	(3,15)/(2,10)	(4,5)	(3,21)	(3,16)	(3,16)
Filter Gauss FWHM (mm)	0	0	3	6.4	5
Matrix size	144 × 144/ 288 × 288	440 × 440	512 × 512	256 × 256	256 × 256
Pixel size (mm)	4 × 4/2 × 2	1.65 × 1.65	1.59 × 1.59	2.73 × 2.73	2.73 × 2.73
Slice thickness (mm)	4/2	2	5	2.79	3.27

^aIn addition to OSEM, clinic FDG PET protocol for the GE Discovery MI also make use of the Q.Clear reconstruction algorithm (Q-param = 400)

^dDigital PET systems


Digital SiPM PET vs. Conventional PMT PET



→ RC comparable between digital and PMT-based PET

→ EARL (2017) surpassed by most recent PET/CT systems

Digital SiPM PET vs. Conventional PMT PET




→ Compared to PMT-based PET, digital systems have comparable image quality for lower TAP (-40% to -70%)

Digital SiPM PET vs. Conventional PMT PET

Conclusions

- Image quality was comparable with a **TAP reduction of >40%** in digital PET
- Leads to significant reduction in mass activity or time with direct benefit for **patient dose exposure and comfort**









2nd Worldwide installation in June 2018, N>5000 patients as of today

Prof. Dr. Dr. John Prior
Lausanne University Hospital

Initial Clinical Experience Digital SiPM-based PET/CT



First patient in Lausanne (June 2018)



PET

CT

PET/CT fusion


PET

CT

PET/CT fusion



Today's Challenge in Oncologic Imaging



Local? → Surgery?
Regional? → Radiation?
Distant? → Chemo?

Identify all lesions is key
to defining right therapy


Local?

Lymph nodes?

Metastases?




Poor spatial resolution
and sensitivity negatively
affects lesion detectability
and staging

55-y uveal melanoma patient




Extensive liver
metastases

55-y uveal melanoma patient



Detectability of small structures in FDG PET/CT


Visual observations of the pituitary gland



Non-Si-PM PET/CT

Gauss filter FWHM = 5mm

Voxel size : 2.74×2.74×3.27 mm




SiPM PET/CT

No gaussian Filter

Voxel size: : 1.65×1.65×2mm

→ **Reduced partial volume effect**


Increased signal recovery from small structures



- Comparison of physiological uptake of a small structure — the pituitary gland (PG) — on dPET and cPET
- Modified NEMA/IEC phantom study with \varnothing 20-, 10-, 7-, 5-, 3- and 2-mm hot spheres
- 3x and 5x higher sphere activity than background concentration
- Acquisition times 1, 2, 3, 5 min
- N=10 patients each in dPET & cPET with measured SUV_{max}, SUV_{mean}, and PG volume

Increased signal recovery from small structures

5x higher activity in spheres vs. background



Spheres \varnothing 20, 10, 7, 5, 3, and 2 mm

→ Superior signal recovery and small region detectability with dPET

Increased signal recovery from small structures

3x higher activity in spheres vs. background



Sphere	<u>1 min</u>		<u>2 min</u>		<u>3min</u>		<u>5min</u>	
	cPET	dPET	cPET	dPET	cPET	dPET	cPET	dPET
20 mm	7.62	7.42	10.33	10.11	13.18	11.95	16.9	15.76
10 mm	2.82	3.68	3.13	5.04	4.05	6.36	5.4	8.15
7 mm	1.2	1.49	1.15	2.7	1.74	3.09	1.97	3.03

5x higher activity in spheres vs. background

Sphere	<u>1 min</u>		<u>2 min</u>		<u>3min</u>		<u>5min</u>	
	cPET	dPET	cPET	dPET	cPET	dPET	cPET	dPET
20 mm	17.55	16.02	23.74	22.25	28.38	27.41	35.67	35.5
10 mm	8.63	10.9	12.09	15.08	12.85	18.2	15.77	23.74
7 mm	5.03	3.33	4.81	5.65	6.04	8.49	6.69	12.34
5 mm	-0.02	4.05	0.5	3.55	0.35	4.37	0.56	4.68

Signal difference to noise ratio: $SDNR > 3$ for detection
(according to EARL 2017)

Increased signal recovery from small structures



Conclusions:

→ Awareness of “higher” SUV of normal pituitary FDG uptake is important to avoid potential pitfalls in interpretation

→ Of importance in oncologic patients under immunotherapy, who are at increased risk to develop hypophysitis (PG inflammation)

Lesion Detectability with Digital PET

European Journal of Nuclear Medicine and Molecular Imaging (2019) 46:1383–1390
<https://doi.org/10.1007/s00259-019-4260-z>

ORIGINAL ARTICLE



Comparison of image quality and lesion detection between digital and analog PET/CT

Diego Alfonso López-Mora¹ · Albert Flotats¹ · Francisco Fuentes-Ocampo¹ · Valle Camacho¹ · Alejandro Fernández¹ · Agustí Ruiz² · Joan Duch¹ · Marina Sizova¹ · Anna Domènech¹ · Montserrat Estorch¹ · Ignasi Carrió¹

Received: 14 November 2018 / Accepted: 2 January 2019 / Published online: 10 January 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Abstract

Objective The purpose of this study was to compare image quality and lesion detection capability between a digital and an analog PET/CT system in oncological patients.

Materials and methods One hundred oncological patients (62 men, 38 women; mean age of 65 ± 12 years) were prospectively included from January–June 2018. All patients, who accepted to be scanned by two systems, consecutively underwent a single day, dual imaging protocol (digital and analog PET/CT). Three nuclear medicine physicians evaluated image quality using a 4-point scale (−1, poor; 0, fair; 1, good; 2, excellent) and detection capability by counting the number of lesions with increased radiotracer uptake. Differences were considered significant for a *p* value < 0.05.

Results Improved image quality in the digital over the analog system was observed in 54% of the patients (*p* = 0.05, 95% CI: 44.2–63.5). The percentage of interrater concordance in lesion detection capability between the digital and analog systems was 97%, with an interrater measure agreement of κ = 0.901 (*p* < 0.0001). Although there was no significant difference in the total number of lesions detected by the two systems (digital: 5.03 ± 10.6 vs. analog: 4.53 ± 10.29; *p* = 0.7), the digital system detected more lesions in 22 of 83 of PET+ patients (26.5%) (*p* = 0.05, 95% CI: 17.9–36.7). In these 22 patients, all lesions detected by the digital PET/CT (and not by the analog PET/CT) were < 10 mm.

Conclusion Digital PET/CT offers improved image quality and lesion detection capability over the analog PET/CT in oncological patients, and even better for sub-centimeter lesions.

Keywords Digital PET/CT · Analog PET/CT · Lesion detection capability · Image quality

N=100 oncological patients
Comparison dPET vs. cPET
Improved image quality in 54 patients

dPET detected more lesions in 22 patients, all <10mm
dPET changed staging in 32% of these 22 patients

CHUV: HF Pulsatile Flow Ventilation Apnea PET/CT

BRIEF COMMUNICATIONS

Reduction of Respiratory Motion During PET/CT by Pulsatile-Flow Ventilation: A First Clinical Evaluation

John O. Prior¹, Nicolas Pigneur^{2*}, Anastasia Pomoni¹, Martin Pappou¹, Michele Zeverio¹, Bastien Belmonte³, Alban Louis⁴, Malmat Ozsabin⁵, Monique Viennet⁶, and Jean Bourhis⁷

¹Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland; ²Department of Radiation Oncology, Lausanne University Hospital, Lausanne, Switzerland; ³Department of Medical Physics, Lausanne University Hospital, Lausanne, Switzerland; ⁴Department of Physiotherapy, Lausanne University Hospital, Lausanne, Switzerland; ⁵Department of Pneumology, Lausanne University Hospital, Lausanne, Switzerland; and ⁶BIRD Institute of Pulmonary Care, Villejuve-Loche, France

Respiratory motion negatively affects PET/CT image quality and quantitation. A novel Pulsatile-Flow Ventilation (PFV) system reducing respiratory motion was applied in spontaneously breathing patients to induce sustained apnea during PET/CT. **Methods:** Four patients (aged 66 ± 14 y) underwent PET/CT for pulmonary nodule staging (mean, 11 ± 7 mm; range, 5–18 mm) at 60 ± 3 min after ¹⁸F-FDG injection and then at 47 ± 7 min afterward, during PFV-induced apnea (each imaging lasting 23.5 min). Anterior-posterior thoracic amplitude, SUV_{max}, and SUV_{mean} (SUV_{mean} in a 1-cm-diameter sphere) were compared. **Results:** PFV PET/CT induced thoracic amplitude (80%), increased mean lesion SUV_{max} (25%), and SUV_{mean} (11%), increased lung background SUV_{max} (25%), improved lesion detectability, and increased SUV_{max} lesion-to-background ratio (84%). On linear regressions, SUV_{max} and SUV_{mean} significantly improved by 35% and 23%, respectively, $P < 0.02$. **Conclusion:** PFV-induced apnea reduces thoracic organ motion and increases lesion SUV, detectability, and delineation, thus potentially affecting patient management by improving diagnosis, prognostication, monitoring, and external-radiation therapy planning.

Key Words: PET/CT; high-frequency Percussive Ventilation; HFV; respiratory motion; Pulsatile-Flow Ventilation

J Nucl Med 2016; 57:416–419
DOI: 10.2967/jnumed.115.163386

PET/CT has become a major oncologic imaging modality for diagnosis, prognostication, therapy monitoring, and radiation therapy planning (1). Respiratory motion has significant negative effects on image quality, on the accuracy with which PET quantifies lesion activity, on fusion accuracy, and on delineation of lesion volume (2). Several advanced PET/CT respiration-gating techniques have been developed to pulsate thoracic organ motion (3). All have intrinsic limitations, such as longer PET acquisitions, mistaking of several tissue positions in a single bin, and difficulty

with irregular breathing patterns. In addition, not only PET but also CT should be gated to avoid introducing supplementary motion correction and quantification errors (2). Today, these techniques are not universally applied and no consensus exists as to the best method to compensate for respiratory motion.

HFV (high-frequency percussive ventilation; OxyCart GmbH) was first designed to promote airway clearance through a percussive flow of air. On the basis of this bysinnic effect, HFV was then developed in intensive care units, with percussive airflow favoring evacuation of atelectatic alveoli secondary to intubation injury (5). The physical principle is to deliver high-frequency ventilation (>400/min) in low ventilation cycles (10–30 cycles/min). Clinical experience demonstrated improved lung compliance, oxygenation, and ventilation compared with conventional ventilation in intensive care. These benefits extended the indication as a salvage modality for acute respiratory distress syndrome, with clinical evidence supported by smaller trials. Successive subtidal brushing with added high-frequency oscillations to both the intubation phase and the extubation phase facilitates oxygen diffusion and carbon dioxide removal. We refined this technique to obtain aspecific respiratory motion stabilization at full inspiration for medical imaging and radiation therapy (4). We achieved apnea lasting 8–16 min, allowing radiation therapy in non-intubated patients (6).

We aimed at establishing Pulsatile-Flow Ventilation (The BIRD Institute of Pulmonary Care, Villejuve-Loche, France) PET/CT (PFV) to suppress respiratory motion and quantify lesion detectability and quantification.

MATERIALS AND METHODS


Patient Population

Four patients (mean age ± SD, 65 ± 14 y) with a pulmonary mass lesion (mean size, 11 ± 7 mm; range, 5–18 mm) deemed suitable for radiation therapy were assessed in this research protocol, which was authorized by the State of Vaud Ethics Committee on Human Research. All patients signed an informed consent form. We had originally enrolled 5 patients (between November 2014 and April 2015), but 1 patient refused to undergo PFV PET/CT. The clinical characteristics of the 4 assessed patients are presented in Table 1.



¹⁸F-FDG PET/CT Acquisition

Images were acquired on a site-of-flight PET/CT scanner (Discovery 690; GE Healthcare) with scatter and prior-spatial-functional recovery corrections, 60 min after injection of ¹⁸F-FDG (3.3 MBq/kg) and after the patients had fasted for at least 6 h (PET); 2 mismatched positions, 47 slices, 256 × 256 matrix, ordered-subsets expectation

A Free-breathing




B Free-breathing




Received July 6, 2015; revision accepted Nov. 16, 2015.
For correspondence or reprint requests, Jean Bourhis, Lausanne University Hospital, Burgon 46, 1011 Lausanne, Switzerland.
E-mail: jean.bourhis@chuv.ch
*Contributed equally to this work.
Published online Dec. 2, 2015.
COPYRIGHT © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.


Free-breathing vs. "Breath-hold" PET



Free-breathing vs. "Breath-hold" PET



Importance for lung cancer screening?




N=6 patients with lung nodule (15 ± 8 mm)

100%, 50% and 10% of activity decimated reconstructions, 90-s/bed position


→ SUV_{mean} decreased by 10% in 0.2 MBq/kg with stable signal-to-background ratio

Ga-68-PSMA-11 PET/CT Staging Primary PCa




62-y Men with
primary PCa


Ga-68-PSMA PET/CT Staging Primary PCa



Ultrafast PET (<5-min)




13-min PET (CBM, 1.5-min/bed equivalent)



5-min PET

→ *Identical SUV measurements*

Ultrafast whole-body PET (<5-min)




15-min PET (CBM, 1.5-min/bed equivalent)

→ *Identical SUV measurements*


5-min PET

Less dose exposition




Brain PET



cPET



dPET



Rubidium-82 Cardiac-PET



5 MBq/kg Rb-82 (86 kg) 430 MBq
6-Min Stress + Rest acquisitions

Reducing Rb-82 activity in cardiac PET/CT




Halved ^{82}Rb -Injected Activity Using High-Resolution, High-Sensitivity and 214-ps SiPM PET/CT in Comparison to a 500-ps System with Standard Activity

Mario Jreige, Christel Kamani, Gilles Allenbach, Martin Paopon,
Patrick Genoud, Silvano Gnesin, Marie Nicod-Lalonde, Niklaus G. Schaefer,
John O. Prior


NUCLEAR MEDICINE DEPARTMENT, LAUSANNE UNIVERSITY HOSPITAL (CHUV),
LAUSANNE, SWITZERLAND

- 10MBq/kg with 500-ps cPET
- 5 MBq/kg with 214-ps dPET
- N=12 individuals with normal MBF in each group

Comparison 10 MBq/kg vs. 5 MBq/kg




500-ps TOF cPET



214-ps TOF dPET

Results





SNMMI Annual Meeting

SS13: Cardiovascular YIA Symposium

12:30 PM - 2:00 PM, Sun, Jun 23, 2019

No. 101
 01:00 PM
Halved⁸²Rb-Injected Activity Using High-Resolution, High-Sensitivity and 214-ps SiPM - PET/CT in Comparison to a 500-ps System with Standard Activity.
 Mario Jreige, Lausanne University Hospital



Y-90 TOF PET after SIRT



20-min PET
high-sensitivity


[19/12/201

Total-Body PET Axial Length vs. Cost



Base Price PET 20-cm → 2 MCHF

Total-body PET (Explorer, 2m)



2 m de long

560'000 cristaux


PET en 30-40 seconds ou 1/40 l'activité habituelle



0 min 0 sec

Total-body PET (Explorer, 2m)


^{68}Ga -PSMA Imaging, with different scan time



82kg, 3.35mCi ^{68}Ga -PSMA, imaged for 10 minutes(left) at 80min post injection.

Image Courtesy of Sun Yat-sen Univ.'s Cancer Center

High sensitivity (total body) imaging




Comparable image quality at 9 hours as today's clinical system at 1 hour


Total-Body PET/CT Captures Full Picture of Systemic Inflammatory Arthritis

uEXPLORER total-body ^{18}F -FDG PET/CT scans in Arthritis


Psoriatic Arthritis



Rheumatoid Arthritis



Osteoarthritis



Low
radiation
dose:
20-min scan
75 MBq
F-18-FDG
→ 1.4 mSv

Total-body PET (Explorer, 2m)

Benefits:

Better

Faster

Later after injection

Lower dose

Total-body dynamic

- Major increase in dynamic range

can image for 5 more half lives

- ^{11}C


> 3 hours

- ^{18}F

> 16 hours

- ^{89}Zr


> 30 days



Long axial FOV PET



1.06-meter



10-min
PET



PET MIP

1 bed position / 10 min per bed



Axial



Coronal

→190 MBq

4-min
PET



PET MIP

1 bed position / 4 min per bed



Axial



Coronal


→76 MBq

1-min
PET



PET MIP

1 bed position / 1 min per bed



Axial



Coronal

→19 MBq

15-s
PET




PET MIP

1 bed position / 15 sec per bed




Axial



Coronal


→5 MBq

PET: 3 major improvements last 3 decades



10-ps TOF PET: Advantages

Next technology?



- 1.5-mm resolution along LOR
- Tomography-less real-time reconstructions (“Anger-camera”-like)
- Total-body with sparse detectors
- Increase PET sensitivity (>16)
- Reduction in activity per dose, reduced price
- Better quantification @low count → ultra low-dose screening (oncology, psychiatric & infectious diseases)

P. Lecoq, C. Morel, J. Prior, 2018

Clinical improvements

Better resolution (tumor microenvironment)

Better sensitivity

Less activity

Image longer (C-11 4h, F-18 20h, Zr-89 30d)

Image faster (respiratory/cardiac/GI movements)

High temporal resolution

200-fold reduction (0.03 mSv = 2.5d natural irradiation)

Image more often

Novel clinical applications (1)

Precise quantification of low-activity metabolism, such as apoptosis (programmed cell death) in myocardial infarct, chronic heart failure, stroke or neurodegeneration (Alzheimer or Parkinson's disease)

→ may help to develop new drugs or better follow and treat disease activity


Novel clinical applications (2)

Lung cancer screening (with CT: now 96% false positive rate) → better with ultra-low-dose PET

Non-fatal disease: tuberculosis (India, China, South Africa, $10 \cdot 10^6$ new cases/ $1.8 \cdot 10^6$ death in 2015), HIV, also

(schizophrenia, mental disorders)

SARS-CoV-2...




Novel clinical applications (3)

Radiation dose equivalent to a few days–weeks of natural radioactivity

Advantages for pediatric NM, but also for fetal growth and placental pathology (obstructive uropathy, brain development, hypoxic insult, abnormal fetal motor behavior and epilepsy) → benefit to percutaneous or fetal surgery, which has entered the clinical arena

10-ps TOF-PET improvement simulation



Non-TOF
FBP



Non-TOF
OSEM



10ps TOF
FBP



10ps TOF
OSEM

Therefore...

Creation of the 10-ps TOF PET Challenge

<http://the10ps-challenge.org>

The 10ps challenge: a step toward reconstructionless TOF-PET



The 10ps challenge:

- a spur on the development of fast timing
- an opportunity to get together
- an incentive to raise funding
- a way to shed light on nuclear instrumentation for medical imaging

One unique challenge launched for 5 to 10 years and operated by an international organisation with rules issued by the community based on the measurement of CTR combined to sensitivity

Several milestones and prizes:

- 3 years after the launch of the challenge: 1M€ expected for the Flash Gordon prizes for the realisation of 3 important milestones
- until the end of the challenge: 1M€ expected for the Leonard McCoy price for the first team meeting successfully the specifications of the challenge



Non-TOF
FBP



Non-TOF
OSEM



10ps TOF
FBP



10ps TOF

<http://the10ps-challenge.org>

Endorsement



EUROPEAN INSTITUTE
FOR BIOMEDICAL
IMAGING RESEARCH



IEEE NPSS NMISC




PETsys
Electronics

Worldwide:
42 PET Scientists
and Physicians



As of January 2021



Physics in Medicine & Biology

Roadmap toward the 10 ps time-of-flight PET challenge

Paul Lecoq¹, Christian Morel², John O'Pryor³, Dimitris Vavakis⁴, Stefan Gundacker⁵,
Hirotoyo Adachi⁶, Peter Krüger⁷, Emma Martinez Torres⁸, Dominique Thers⁹, Edouardo Charbon¹⁰,
Juan Varela¹¹, Christophe De La Taille¹², Angelo Rivetti¹³, Dominique Beynon¹⁴, Jean-François Pottier¹⁵,
John Norris¹⁶, Stefano Sarti¹⁷, Stefano Vandenberghe¹⁸, Paul Meulen¹⁹, Kasia Kosow²⁰, Jozsef Marton²¹
and Mathieu Benoit²²

Abstract

Since the seventies, positron emission tomography (PET) has become an invaluable medical
molecular imaging modality with an unprecedented sensitivity at the picomolar level, especially for
cancer diagnosis and the monitoring of its response to therapy. More recently, its combination with
x-ray computed tomography (CT) or magnetic resonance (MR) has added high precision
anatomic information in fused PET/CT and PET/MR images, thus compensating for the modest
intrinsic spatial resolution of PET. Nevertheless, MR has added high precision
improvements in PET sensitivity. These concerns, in particular, new treatment opportunities in the
context of personalized (also called precision) medicine, such as the need to detect a small
number of cells in cancer immunotherapy or stem cells for tissue repair procedures, by better
signal-to-noise ratio (SNR) in the image would allow detecting smaller lesions and track a small
better staging of the patients, thus increasing the chances of putting cancer in remission. However,
the patients without impacting image quality.
Moreover, there is an increasing demand for reducing the radioactive doses injected to
the patients without impacting image quality.
There are three ways to improve PET scanner sensitivity: improving detector efficiency,
increasing geometrical acceptance of the imaging device and pushing the timing performance of
detection of the photons, whose accuracy is given by the coincidence time resolution (CTR). A
CTR of about 10 picoseconds FWHM will ultimately allow in obtaining a submilli-sec 3D volume

- Hossein Javid, University of Southern California, Los Angeles, USA
- Jae Sung Lee, Seoul National University, South Korea
- Terry Jones, UK
- Nikolaos Karakatsani, Cornell University, New York, USA
- Mark Ladd, DKFZ, Heidelberg, Germany
- Roger Lecomte, University of Sherbrooke, Canada
- Paul Lecoq, CERN, Geneva, Switzerland
- Homer A. Macapinlac, UT MD Anderson Cancer Center, Houston, USA
- Steven Meikle, University of Sydney, Australia
- Laurent Minard, IMNC, University Paris Descartes, France
- Jozsef Marton, University of Medicine
- Dimitris Vavakis, University of Medicine
- Dominique Yvon, CEA-IRFU, Saclay, France
- Karl Ziemons, FH-Aachen University of Applied Sciences, Germany

Part 2

Hybrid whole-body CZT gamma-camera

Hybrid whole-body CZT gamma-camera



(NM/CT 670 CZT)
NM/CT 870 CZT





VERITON-CT


↙ ↘
Different collimation systems

CZT detectors for nuclear imaging

1. **Direct** detection enabling **high detection efficiency**
2. **Small pixelated** detectors (2.46 mm, compact design)
3. **High energy resolution** (2 x higher than NaI(Tl))
4. **Currently a maximal energy** in the range ~ 200 keV for the detected photons



360° CZT VERITON™ system



12 detectors
8 CZT modules per
detector




Swiveling detectors in
close proximity to the
patient

Direct photon conversion


Full 360° FOV Scan

Projections acquired
from the entire FOV



Focused 360°FOV Scan

80 to 100% of the
projections acquired
directly from a ROI



Myocardial perfusion SPECT

Decreased Activity & Time
Cardiac dynamic SPECT possibility (software exists)


Patient 01

Sex F
160 cm / 52 kg

Stress:
103 MBq – 10 min

Rest:
290 MBq – 5 min

**Anterior
infarction**




Patient 02

Sex M
173 cm / 85 kg

Stress:
150 MBq – 10 min

Rest:
461 MBq – 5 min


**Apical
ischemia**



Organ and whole-body imaging



Hybrid whole-body CZT imaging



Dedicated brain perfusion SPECT

ARTICLE IN PRESS

Available online at ScienceDirect Elsevier Masson France EM consulte

Correspondence

Brain perfusion SPECT acquired using a dedicated brain configuration on a 360° whole-body CZT-camera

ARTICLE INFO

Keywords:
Brain perfusion;
CZT;
SPECT;
Contrast;
Spatial resolution;
Image quality

Dear editor,

The development of whole-body cadmium zinc telluride (CZT) cameras contributes to recent advances in single photon emission computed tomography (SPECT) imaging, owing to high energy and spatial resolution of these CZT detectors [1]. These new type of cameras are now commercially available and have been so far studied for bone scintigraphy [2].

The Veriton-CT™ (Spectrum Dynamics Medical®) is a hybrid whole-body CZT-camera equipped with 12 swiveling, high-resolution CZT detectors regularly spaced over 360 degrees. This system has the advantages of CZT detector features (1.3–5) and additionally benefits from 360° detector geometry which allows positioning of the detectors close to the patient's head and to focus the acquisition in a specific brain configuration (Fig. 1A).

An 81-year-old female presenting with neurocognitive impairment underwent brain perfusion SPECT acquisition [16,3]


15 minutes after a neurosensory resting period following the injection of 606 MBq of ^{99m}TcTechnetium Labeled HMPAO [1], firstly with a conventional Anger-SPECT camera (Symbia T2™, Siemens Healthineers; parallel-hole collimators; 30-minutes acquisition) equipped with parallel-hole collimators and thereafter, with the Veriton™ CZT-camera, using the dedicated brain configuration (15-minutes acquisition). Axial slices of brain SPECT images obtained on both systems are presented in Fig. 1B and were optimized with a similar level of convergence of the iterative reconstruction process and CT slices (B) were used for further corrections of attenuation.

Tomographic count sensitivity was enhanced by a factor 2 with CZT as compared with Anger-SPECT (10.19 vs. 5.21 Mcounts/sec after decay correction) and signal-to-noise ratio was enhanced by a factor 1.5 (9.6 vs. 6.3) with CZT, measured within a homogeneous area centered on the semi-oval centre. Spatial resolution and contrast of the CZT-SPECT images were also clearly enhanced, thus providing better visualization of the hypo-perfused areas associated with cortical atrophy (red arrows). It is likely that such improvements in both detection sensitivity and image quality will enhance the SPECT assessment of neurocognitive disorders [1], although this remains to be demonstrated by further dedicated studies.


To our acknowledgment, this is the first reported case of brain images obtained with a CZT-SPECT system, directly compared to a classical Anger-SPECT system. This distinct improvement in image quality, associated with a high potential for reducing acquisition time and/or injected activity, could support wider applications for brain perfusion SPECT studies, such as in ictal epileptic conditions [8] and for functional analyses of brain activation [9].

Improved image quality, potential to decrease activity or time

Bordonne M et al, J Neurorad 2019



Hybrid whole-body CZT imaging



European Journal of Nuclear Medicine and Molecular Imaging
<https://doi.org/10.1007/s00259-019-04525-y>

IMAGE OF THE MONTH

Augmented planar bone scintigraphy obtained from a whole-body SPECT recording of less than 20 min with a high-sensitivity 360° CZT camera

Saïfeddine Melki¹ · Mohammad Bilal Chawki^{1,2} · Pierre-Yves Marie^{1,3} · Laetitia Imbert^{1,3,4} · Antoine Verger^{1,3,4}

Received: 12 June 2019 / Accepted: 4 September 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Low-dose CT (<2 mSv)
(6 to 7) x (3-min bed position)

Melki S et al. EJNMMI 2019

Unil
UNIL | Université de Lausanne

CUV

SPECT/CT with GE 670 CZT

A Swiss experience

Courtesy of Renaud Guignard, MD, La Tour Hospital, Geneva, Switzerland

Cardiac MPI with hybrid whole-body, CZT-based camera

GE 670 CZT installed in June 2018, first 2 years: >800 MPI studies

Prone position (>75%), systematic gated-SPECT and (stress) CTAC

2 protocols:

- **1-day stress-rest** (90% of patients) with stress first and rest only performed if abnormal stress results
- **2-day stress-rest** for obese patients in screening setting (BMI > 35 kg/m²)

Radiopharmaceutical: ^{99m}Tc-tetrofosmin

Pharmaceutical stress agent: regadenoson 400µg/5mL

Average total counts: 7 million counts (stress) / 25 million counts (rest)

Patient history:

- 68 year-old man; 123 kg (BMI 40.2)
- effort dyspnea; no history of CAD
- Negative pharmacologic stress test

Technical parameters:

- 1200 MBq ^{99m}Tc -tetrofosmin (*CT-scan DLP: 21 mGy.cm⁻¹*)
- Supine position; 2 day-protocol



Stress-rest myocardial perfusion images (NAC)

QGS stress results

LVEF: 60%
EDV: 142 mL
ESV: 57 mL

QGS rest results

LVEF: 65%
EDV: 135 mL
ESV: 48 mL



7.5-min

7.5-min

NAC

Decreased Acquisition
Time by 30–40%

SPECT-CT acquisitions (real time \approx 10 minutes)

30 x 2 projections; 15 seconds/bed
(L-configuration; 64x64; zoom 1.3; orbit:180°)

Reconstruction parameters:

OSEM 2it10sub; BW filter 0.4/10; +/- AC corrections

Patient history:

- 68 year-old man; 123 kg (BMI 40.2)
- effort dyspnea; no history of CAD
- Negative pharmacologic stress test

Technical parameters:

- 1200 MBq ^{99m}Tc -tetrofosmin (CT-scan DLP: 21 mGy.cm⁻¹)
- Supine position; 2 day-protocol


Stress-rest myocardial perfusion images (AC)

QGS stress results

LVEF: 60%
EDV: 142 mL
ESV: 57 mL

QGS rest results

LVEF: 65%
EDV: 135 mL
ESV: 48 mL



7.5-min

7.5-min

CONCLUSION

- No significant perfusion defect
- Inferior wall attenuation

SPECT-CT acquisitions (real time \approx 10 minutes)

30 x 2 projections; 15 secondes/bed
(L-configuration; 64x64; zoom 1.3; orbit:180°)

Reconstruction parameters:

OSEM 2it10sub; BW filter 0.4/10; +/- AC corrections

Lung scan

No pulmonary embolism



Technical parameters:

- 80y old woman; 106 kg; BMI 41.1; supine position
- V: Technegas/ Q: 200 MBq ^{99m}Tc -MAA (CT-scan DLP: 92 mGy.cm⁻¹)

VENTILATION (coronal AC view)




PERFUSION (coronal AC view)



WB bone scan + 3FOV SPECT («PET-like») for oncological purpose

Technical parameters:



- 73y old man; 75 kg; BMI 29.3; supine position
- 781 MBq ^{99m}Tc -nanocolloid (CT-scan DLP: 620 mGy.cm⁻¹)
- Injection-acquisition time: 3 hours



DATscan (+analysis)



Technical parameters:

- 82y old man; 77 kg; BMI 23.8; supine position
- 191 MBq ^{123}I -Ioflupane
- Injection-acquisition time: 3 hours







Unique dual-isotope simultaneous acquisition (CZT-improved energy resolution)


Cortical Region	Patient	Normal	Diff.	Z-Score
Prefrontal Lateral R	0.87	0.96	-0.09	-4.49
Prefrontal Lateral L	0.85	0.95	-0.11	-5.76
Prefrontal Medial R	0.84	0.95	-0.11	-3.53
Prefrontal Medial L	0.87	0.95	-0.07	-2.18
Sensorimotor R	0.98	0.94	0.03	1.28
Sensorimotor L	0.94	0.95	-0.00	-0.05
Anterior Cingulate R	0.85	0.93	-0.08	-1.53
Anterior Cingulate L	0.82	0.94	-0.12	-2.36
Posterior Cingulate R	1.01	0.99	0.02	0.54
Posterior Cingulate L	0.99	0.98	0.00	0.04
Precuneus R	1.13	1.00	0.13	3.99
Precuneus L	1.13	0.98	0.15	3.86
Parietal Superior R	0.99	0.91	0.08	1.92
Parietal Superior L	0.88	0.87	0.01	0.31
Parietal Inferior R	0.98	0.97	0.01	0.50
Parietal Inferior L	0.89	0.95	-0.06	-2.36
Occipital Lateral R	1.07	0.92	0.16	6.15
Occipital Lateral L	1.04	0.92	0.12	5.67
Primary Visual R	1.14	1.00	0.14	2.77
Primary Visual L	1.03	1.01	0.02	0.68
Temporal Lateral R	0.77	0.93	-0.16	-6.75
Temporal Lateral L	0.85	0.92	-0.07	-3.14
Temporal Mesial R	0.75	0.85	-0.10	-2.85
Temporal Mesial L	0.77	0.86	-0.09	-2.44
Cerebellum	0.95	0.93	0.02	0.69
Pons	0.83	0.87	-0.04	-0.70



Ceretec™ & DATscan™




Comparison of whole-body vs. cardiac CZT



- Acquisitions in phantom and N=10 patients
- Spatial resolution was identical
- Count sensitivity was 2x smaller with whole-body CZT with lower sharpness index and contrast-to-noise ratio
- Wall thickness and LV volumes were identical

High-speed scanning of ^{123}I -mIBG planar images using a whole-body CZT camera



- N=36 patients
- List-mode acquisition
- Acquisition duration of 300-, 200-, 100- and 50-s
- → acquisition time can be reduced by 5x


Summary: Digital PET/SPECT Cameras

PET:

- Improved detectability & quantification in smaller structures, clinical impact++
- **Lower injected activity AND scan duration**
- Total-body PET: new horizons in systems biology imaging, high \$\$\$
- 10-ps TOF PET Challenge: opportunity for even higher sensitivity (202X?)

SPECT:

- Increased energy resolution (2x better)
- Increased resolution as compared to conventional NaI camera
- Clinical impact less clear
- **Lower scan duration OR less often decrease injected activity**
- Only low-medium energy (no ^{131}I , not optimal for ^{111}In , ^{177}Lu)
- Electronic collimation (202X?)



Lausanne,
Switzerland

Thank you for your attention!

<http://the10ps-challenge.org>